Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.37 | N/A | -15.85% |
management commentary, guidance changes, and full analysis available with Pro.
| -15.85% |
Tone: Cautiously Optimistic
Overall, management acknowledged the current hurdles but remains focused on future growth opportunities. They are committed to navigating the competitive landscape.
Management highlighted ongoing challenges in the market but expressed confidence in long-term strategies.
They emphasized the importance of upcoming product launches.
This earnings report indicates that Gilead Sciences faced challenges in meeting earnings expectations, with a notable EPS miss. The lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction is not available, but the management's cautious optimism suggests they are focused on overcoming current market difficulties.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERIPRISE FINL INC
Apr 24, 2023